Organon & Co

Country

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

10,000

Ticker

OGN

Exchange

NEW YORK STOCK EXCHANGE, INC.

Website

www.organon.com

Description

Organon & Co. is a global healthcare company that focuses primarily on the discovery, development, manufacture, and commercialization of therapeutic solutions. Its primary function is to address the n... Show more

Financial Statements of Organon & Co

Below are the financial statements of Organon & Co, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	675^a	693^a
Accounts receivable (net of allowance for doubtful accounts of $14 in 2024 and $9 in 2023)	1,358^a	1,744^a
Inventories (excludes inventories of $215 in 2024 and $110 in 2023 classified in other assets)	1,321^a	1,315^a
Other current assets	994^a	756^a
Total current assets	4,348^a	4,508^a
Assets	—	—
Property, plant and equipment, net	1,168^a	1,183^a
Goodwill	4,680^a	4,603^a
Intangibles, net	1,414^a	533^a
Other assets	1,491^a	1,231^a
Total assets	13,101^a	12,058^a
Current liabilities	—	—
Current portion of long-term debt	20^a	9^a
Trade accounts payable	1,153^a	1,314^a
Accrued and other current liabilities	1,411^a	1,389^a
Income taxes payable	134^a	206^a
Total current liabilities	2,718^a	2,918^a
Liabilities and equity	—	—
Long-term debt	8,860^a	8,751^a
Deferred income taxes	74^a	47^a
Other noncurrent liabilities	977^a	412^a
Total liabilities	12,629^a	12,128^a
Organon & Co. stockholders’ equity (deficit)	—	—
Common stock, $0.01 par value authorized - 500,000 issued and outstanding - 257,799 in 2024 and 255,626 in 2023	3^a	3^a
Additional paid-in capital	108^a	25^a
Retained earnings	1,010^a	443^a
Accumulated other comprehensive loss	-649^a	-541^a
Total stockholders’ equity (deficit)	472^a	-70^a
Total liabilities and stockholders’ equity (deficit)	13,101^a	12,058^a

Verified Sources Behind Organon & Co’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Organon & Co’s data sources below and access millions more through our Disclosure Search.

a. Organon & Co's 10-K 2024

Trace every data point back to Organon & Co’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Organon & Co

Financial Statements of Organon & Co

Verified Sources Behind Organon & Co’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Merck & Co Inc

Biogen Inc

Gilead Sciences Inc

Zimmer Biomet Holdings Inc

Royalty Pharma PLC

Moderna Inc